OneMedNet Corp (ONMD)
ONMD trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1849380/000149315226013681/0001493152-26-013681-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ONMD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United Kingdom |
| IPO year | 2021 |
| SEC CIK | 0001849380 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.4M |
| Net income | -$2.8M |
| Operating income | -$9.7M |
| Net margin | -206.1% |
| Operating margin | -711.3% |
| Revenue growth | +111.4% |
| Cash | $585K |
| Total assets | $2.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 21.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Therefore, these conditions raise substantial doubt about the Company's ability to continue as a going concern. 6 To continue and expand its operations, the Company will be required to, and management plans to, raise additional working capital through equity or debt offerings and ultimately hopes to attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of " | 10-Q 2026-08-14 |
| Cash and burn | $358K cash; operating cash flow -$1.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 5,928,645 (2026-08-11); 46,095,647 a year earlier; 32,263,342 three years earlier. | Cover page 2026-08-11 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2026-09-29 | Source 2026-09-29 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-20 |
| Auditor | WithumSmith+Brown, PC, East Brunswick, New Jersey, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $3.2M, sold $218K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $292K | -$2.2M | -$1.9M | $358K | $132K | $1.5M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $96K | -$2.5M | -$1.5M | $233K | $176K | $1.3M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $891K | -$3.1M | -$1.7M | $585K | $220K | $1.4M | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $177K | -$741K | -$1.7M | $149K | $388K | $495K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $155K | $3.0M | -$2.2M | $122K | $400K | $460K | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $137K | -$1.9M | -$1.9M | $144K | $4.7M | $532K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $26K | -$2.4M | -$2.0M | $172K | $4.6M | $643K | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | $142K | -$2.1M | -$1.9M | $1.9M | $4.6M | $957K | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-16 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEF 14A | 2026-08-19 |
Source: SEC EDGAR submissions feed, 295 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.9% |
| 1 month | +32.8% |
| 3 months | -31.3% |
| Year to date | -51.5% |
| 1 year | -62.1% |
| From 52-week high | -72.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| ONMDW | OneMedNet Corp Warrant | $0.0120 |
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
| BIAF | bioAffinity Technologies Inc. | $2.00 | -9.09% | $3.6M |
| ISPC | iSpecimen Inc. | $0.6049 | -8.17% | $3.3M |
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier